Summary
Development of a platform encapsulation technology for delivering stabilized therapeutic microbes (probiotics) in infant formula powder to prevent Necrotizing Enterocolitis (NEC) in preterm infants.
Platform technology for delivery of stabilized therapeutic microbes in powders with high water activity
US · IL
NIH
grant
awarded
#nih-1R43HD117653-01
What they want
The project aims to expand a patented encapsulation technology to use materials approved for infant formula powder. This involves examining multiple excipients in the formulation, evaluating gastric stability, targeted intestinal release, maintenance of stable/viable microbes, and shelf stability. The goal is to develop formulations with probiotic species reported to reduce NEC occurrence, specifically designed for the unique GI tract of neonates.
Deliverables
- Formulations with probiotic species designed for neonates
Technical requirements
- Patented platform encapsulation technology
- Use materials approved for infant formula powder
- Achieve gastric stability
- Enable targeted intestinal release
- Maintain stable/viable microbes
- Ensure shelf stability
Risks & flags
Incumbent: VitaKey
- Project is based on a specific patented platform technology already developed by 'VitaKey', indicating a potential sole-source justification or wired opportunity.
